Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study

Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation (ASCT), are the standard of care for patients with newly diagnosed multiple myeloma (NDMM). Pomalidomide is currently approved for relapsed-refractory multiple myeloma. This sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Saj, Fen, Nisha, Yadav, Ganesan, Prasanth, Kayal, Smita, Kar, Rakhee, Halanaik, Dhanapathi, Dubashi, Biswajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039009/
https://www.ncbi.nlm.nih.gov/pubmed/36964143
http://dx.doi.org/10.1038/s41408-023-00816-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039009/
https://www.ncbi.nlm.nih.gov/pubmed/36964143
http://dx.doi.org/10.1038/s41408-023-00816-8

Ejemplares similares